Performance analysis of Cidara Therapeutics (CDTX)
Annual Return
Over the past 3 years, CDTX has had an average annual return of +127.60%, outperforming the benchmark SPY, which returned +21.95% annual.
Over the past 5 years, CDTX has had an average annual return of +43.86%, outperforming the benchmark SPY, which returned +12.84% annual.
Over the past 10 years, CDTX has had an average annual return of -0.19%, underperforming the benchmark SPY, which returned +15.03% annual.
Since Apr 15, 2015, CDTX has had an average annual return of -3.37%, underperforming the benchmark SPY, which returned +13.60% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +0.22% | +721.79% | +69.35% | +4.86% | -40.43% | -36.48% | -47.92% | +63.38% | -65.44% | -34.62% | -39.39% | +7.25% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.22% | +0.22% | |||||||||||
| 2025 | -30.95% | +34.14% | -13.50% | -2.97% | +3.83% | +124.48% | +29.96% | +3.29% | +46.50% | +14.07% | +101.26% | +0.47% | +721.79% |
| 2024 | -19.15% | +10.22% | +30.09% | -34.96% | +6.15% | -6.05% | +9.92% | -9.27% | -9.68% | +20.83% | +55.67% | +32.91% | +69.35% |
| 2023 | +62.58% | +22.76% | -15.89% | -19.65% | +30.25% | -15.04% | -11.90% | -21.22% | +20.20% | -18.68% | -7.52% | +11.96% | +4.86% |
| 2022 | -28.97% | -22.34% | +18.72% | -16.15% | -33.94% | +5.90% | +60.98% | -13.44% | -7.53% | -2.29% | +4.17% | +18.25% | -40.43% |
| 2021 | +22.48% | -7.32% | +17.20% | -16.60% | -8.94% | +0% | -24.78% | +51.37% | -2.64% | -29.43% | -5.77% | -14.72% | -36.48% |
| 2020 | -17.96% | -7.92% | -14.51% | +14.13% | +27.93% | +1.90% | -1.08% | -12.85% | -10.41% | -8.42% | -10.30% | -14.56% | -47.92% |
| 2019 | +23.42% | +0% | -8.66% | -15.10% | -28.45% | +4.37% | -15.43% | +18.24% | +18.76% | +9.78% | +7.30% | +63.38% | +63.38% |
| 2018 | +5.15% | -6.29% | -40.31% | +7.52% | +30.21% | -7.14% | -19.23% | +1.18% | +3.54% | -10.69% | -7.37% | -35.43% | -65.44% |
| 2017 | -4.80% | -27.28% | +8.33% | -0.64% | -22.58% | +25.01% | -6.68% | -1.42% | +17.39% | -4.94% | +2.60% | -13.93% | -34.62% |
Drawdown analysis of Cidara Therapeutics (CDTX)
The maximum drawdown for the CDTX was -97.52%, occurring on May 13, 2022. This drawdown has not yet recovered.
The current CDTX drawdown is -35.87%.
Since Apr 15, 2015 CDTX has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 2 times
- 10% or more: 4 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.52% | Dec 30, 2015 | 1604 | May 13, 2022 | Ongoing | Ongoing | Ongoing |
| -25.52% | May 18, 2015 | 93 | Sep 29, 2015 | 47 | Dec 4, 2015 | 140 |
| -13.00% | Apr 15, 2015 | 12 | May 1, 2015 | 9 | May 14, 2015 | 21 |
| -10.08% | Dec 7, 2015 | 5 | Dec 14, 2015 | 11 | Dec 30, 2015 | 16 |